Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Infections and infestations – page 2

  • 686 clinical trials
  • 263 recruiting
  • 279 conditions
  • 27 countries

Conditions in this area

279 conditions with trials, the busiest first

HIV infection78COVID-1939Pneumonia32Influenza29Sepsis29Respiratory syncytial virus infection20Post-acute COVID-19 syndrome19Urinary tract infection19Septic shock17Chronic hepatitis B16Bacterial infection14Hepatitis D14Cytomegalovirus infection13Appendicitis10Hepatitis B10Pneumonia bacterial10Fungal infection9Irritable bowel syndrome8Medical device site joint infection8Pyelonephritis acute7Staphylococcal bacteraemia7Staphylococcal infection7T-cell type acute leukaemia7Lower respiratory tract infection6+255

Clinical trials in Infections and infestations

686 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

686 clinical trials

Infectious pleural effusion

Recruiting

Intrapleural Alteplase and Dornase Alfa versus VATS for Patients with Pleural Empyema (Parapneumonic Pleural Infection)

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:Amsterdam UMC Stichting

Respiratory syncytial virus infection

Recruiting

Effectiveness of respiratory syncytial virus glycoprotein F (pre‑fusion) vaccine adjuvanted with AS01E in preventing RSV‑related respiratory disease hospitalization in adults ≥60 years

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
  • Sponsor:Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana

HIV infection

Recruiting

Switching to Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults with HIV-1: A Phase 3 Randomized Study

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abacavir
  • Sponsor:Gilead Sciences Inc.

HIV infection

Recruiting

Switching to lenacapavir-based drug combination vs cabotegravir-based drug combination in virologically suppressed adults with HIV-1

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cabotegravir
  • Sponsor:Gilead Sciences Inc.

Early switch to oral amoxicillin (drug combination) for adults with vertebral osteomyelitis: a randomised non‑inferiority trial

Recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin
  • Sponsor:University Of Cologne

Pneumonia bacterial

Recruiting

Rifabutin plus drug combination for adult patients with hospital‑acquired and ventilator‑associated pneumonia caused by carbapenem‑resistant Acinetobacter baumannii

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Ampicillin Sodium
  • Sponsor:Bioversys S.A.S.

Measles+3

Recruiting

Long‑term immunity after a 6‑month‑old MMR vaccine (live attenuated) in infants: follow‑up of antibody levels 1‑3 years after routine vaccination

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · Healthy volunteers
  • Substances:MUMPS VIRUS RIT 4385 STRAIN (LIVE, ATTENUATED) DERIVED FROM FROM THE JERYL LYNN PRODUCED IN CHICK EMBRYO CELLS
  • Sponsor:Rigshospitalet

Post-acute COVID-19 syndrome

Recruiting

Study of Fludeoxyglucose (18F) PET Imaging of Brain Metabolism in Patients with Persistent Post‑COVID Syndrome

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · Healthy volunteers
  • Substances:Fludeoxyglucose (18F)
  • Sponsor:Amsterdam UMC Stichting

Epstein-Barr virus infection

Recruiting

Safety and Tolerability of Tenofovir Alafenamide Dose Escalation in Healthy Adults for Epstein‑Barr Virus Infection

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Tenofovir Alafenamide
  • Sponsor:Helse Bergen HF

Bronchiolitis

Recruiting

Efficacy of Tezepelumab in Treating Bronchiolitis Obliterans Syndrome in Allogeneic Stem Cell Transplant Recipients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:Hospital Foch

Sepsis+1

Recruiting

Acetylcysteine for Adults with Acute Infection or Sepsis and Liver Dysfunction

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Acetylcysteine
  • Sponsor:Rigshospitalet

Rabies

Recruiting

Rabies Prophylaxis in Healthy Volunteers After Rabies Virus (Inactivated) Strain Flury LEP Vaccination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:Rabies virus (inactivated) strain Flury LEP
  • Sponsor:Institute Of Tropical Medicine

Substances studied in this area

The therapies tested most often in Infections and infestations trials.

Sodium Chloride52 clinical trialsAmoxicillin35 clinical trialsEmtricitabine33 clinical trialsTenofovir Alafenamide33 clinical trialsLinezolid32 clinical trialsClavulanic Acid28 clinical trialsRifampicin25 clinical trialsSulfamethoxazole25 clinical trialsTrimethoprim25 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.